For female dialysis-dependent patients aged 65 years or older treated for osteoporosis, denosumab is associated with an increased incidence of severe or very severe hypocalcemia, according to a study. Steven T. Bird, Ph.D., Pharm.D. and colleagues examined the incidence and comparative risk for severe hypocalcemia with denosumab versus oral bisphosphonates in a retrospective cohort study involving female dialysis-dependent Medicare patients aged 65 years or older treated for osteoporosis. The main outcomes were severe hypocalcemia, defined as total albumin-corrected serum calcium <7.5 mg/dL or a primary hospital or emergency department hypocalcemia diagnosis, and very severe hypocalcemia (serum calcium <6.5 mg/dL). Overall,...